|
Treatment
|
Reference
|
OR (95 % CrI)
|
RR (95 % CrI)
|
RD % (95 % Crl)
|
|---|
|
CYC
|
PRED
|
3.81 (1.26, 14.31)
|
2.64 (1.18, 7.51)
|
0.25 (0.04, 0.47)
|
|
MMF
| |
0.48 (0.09, 3.04)
|
0.52 (0.11, 2.58)
|
−0.07 (−0.23, 0.13)
|
|
AZA
| |
2.74 (0.26, 28.27)
|
2.12 (0.30, 8.18)
|
0.17 (−0.15, 0.65)
|
|
CYC LD
| |
9.06 (0.63, 121.50)
|
3.79 (0.68, 11.71)
|
0.45 (−0.06, 0.81)
|
|
MMF
|
CYC
|
0.13 (0.03, 0.41)
|
0.20 (0.05, 0.56)
|
−0.31 (−0.47, −0.16)
|
|
AZA
| |
0.69 (0.09, 5.08)
|
0.79 (0.14, 1.95)
|
−0.08 (−0.37, 0.36)
|
|
CYC LD
| |
2.23 (0.23, 23.20)
|
1.46 (0.34, 2.71)
|
0.19 (−0.27, 0.55)
|
|
AZA
|
MMF
|
5.25 (0.78, 54.39)
|
3.68 (0.81, 19.08)
|
0.22 (−0.02, 0.68)
|
|
CYC LD
| |
16.35 (1.97, 247.70)
|
6.49 (1.72, 30.95)
|
0.50 (0.06, 0.87)
|
|
CYC LD
|
AZA
|
3.20 (0.55, 21.24)
|
1.69 (0.68, 6.12)
|
0.22 (−0.11, 0.60)
|
|
Random-effects model
|
Residual deviance
|
15.93 vs. 17 data points
|
| |
Deviance information criteria
|
72.233
|
|
Fixed-effects model
|
Residual deviance
|
16.16 vs. 17 data points
|
| |
Deviance information criteria
|
72.069
|
- Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trial
- Significant odds ratios are in italics
- For absolute rates for events used for calculation of risk difference, please see Appendix 6
- OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
- The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients
